Background and Aims Lower gastrointestinal endoscopy is crucial in the diagnosis and staging of inflammatory bowel disease (IBD). However, there are limited safety data in pregnant populations, resulting in conservative society guidelines and practice patterns favoring diagnostic delay. We studied whether performance of flexible sigmoidoscopy is associated with adverse events in pregnant patients with known or suspected IBD. Methods A retrospective cohort study was conducted at the University of California San Francisco (UCSF) between April 2008 and April 2019. Female patients aged between 18 and 48 years who were pregnant at the time of endoscopy were identified. All patient records were reviewed to determine disease, pregnancy outcomes, and lifestyle factors. Two independent reviewers performed the data abstraction. Adverse events were assessed for temporal relation with endoscopy.
Introduction
The pregnant woman with active inflammatory bowel disease (IBD) presents management challenges to the treating physician. Among women with IBD at the time of conception, 36% of ulcerative colitis (UC) [1] and 33% of Crohn's disease (CD) [2] patients will experience an increase in disease activity. Active disease is associated with increased risk of adverse pregnancy outcomes, including spontaneous abortion, preterm birth, and low birth weight [3, 4] . Accurately assessing IBD activity in the pregnant patient has significant ramifications on therapeutic decisionmaking and pregnancy outcome.
There are several challenges in accurately establishing IBD activity during pregnancy. Due to physiologic changes and alterations in gastrointestinal motility, pregnancyassociated gastrointestinal symptoms-abdominal pain, constipation, hemorrhoids and diarrhea-can mimic symptoms of an IBD flare [5] . Noninvasive markers of inflammation-such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)-lose their predictive value in pregnancy [6, 7] . While levels of fecal calprotectin (FCP) have been shown to be elevated in pregnant patients with IBD, there is currently no established cutoff for FCP that effectively predicts disease activity in pregnant IBD patients [7] . Furthermore, several meta-analyses have suggested that there is a significant false positive rate, which in the pregnant patient would lead to inappropriate exposure to escalated IBD therapy [8] [9] [10] . Therefore, endoscopic evaluation is critical in accurately staging the severity of IBD in pregnancy and avoiding delay in care.
Theoretical concerns about endoscopy leading to fetal loss, premature delivery, congenital anomalies from medication exposure, and fetal hypoxia from increased intra-abdominal pressure have limited its use during pregnancy. The paucity of data has led the American Society of Gastrointestinal Endoscopy (ASGE) to recommend that endoscopy be deferred to second trimester whenever possible [11] . However, delayed diagnostic workup of a suspected IBD flare in a pregnant patient has serious consequences, as does empiric therapy with biologics and immunosuppressants.
Based on the paucity of studies of lower endoscopy in pregnancy, larger numbers are needed to fully understand the risks versus benefits in pregnant IBD patients. The aim of this study is to investigate whether flexible sigmoidoscopy is associated with adverse events in pregnant patients with IBD.
Methods
A retrospective cohort study was conducted at the University of California San Francisco (UCSF) between April 2008 and April 2019. Institutional ethics approval was obtained (IRB 18-26237). Structured EHR data were extracted from the UCSF Epic system using Clarity and Caboodle tools [12] . Prior to being used for this study, the data were de-identified to comply with the US Department of Health and Human Services 'Safe Harbor' guidance. This database was queried to identify female patients aged between 18 and 48 years inclusive of diagnosis codes corresponding to IBD, melena, hematochezia, or diarrhea and procedure billing codes corresponding to lower gastrointestinal endoscopy. Additional patients were separately identified from a database of endoscopic reports using keyword-based search (see Supplemental Methods). All records meeting the above criteria were subsequently assessed by two independent reviewers (MK, PA) to confirm pregnancy status at the time of lower gastrointestinal endoscopy.
Eligible patient records were further reviewed to determine disease, lifestyle factors (smoking during pregnancy, history of alcohol and recreational drug use, and folic acid use during pregnancy), bowel preparation, and pregnancy outcomes (history of preterm birth, low birthweight, mode of delivery, gestational diabetes, gestational hypertension, oligo-or polyhydramnios, chorioamnionitis, and premature rupture of membranes). Each patient's endoscopic findings were reviewed and recorded as normal, mild, moderate, or severe inflammation based on the reported Mayo Endoscopic score (0 = normal, 1 = mild, 2 = moderate, or 3 = severe) or the description of findings noted on the endoscopist's report. All adverse events were assessed for temporal relation (defined as within 4 weeks) to endoscopy. Any discrepancies in the two reviewers' data were further reviewed by a third independent investigator (VAR).
Descriptive statistics of continuous data were calculated as means and medians with standard deviation and interquartile ranges [IQR], respectively. Categorical data were reported by absolute numbers and percentages. Comparisons of continuous data were made using t tests with unequal variance for normally distributed data, the Wilcoxon rank-sum test, or the Jonckheere-Terpstra trend test [13, 14] . Comparisons of categorical data were calculated using Fisher's exact test.
Results
In total, 48 pregnant patients underwent 47 flexible sigmoidoscopies and 3 colonoscopies. Forty-one (85%) of these patients had a diagnosis of IBD (7 Crohn's disease, 34 Ulcerative Colitis). Median maternal age was 33 years [IQR: 4] and 34 years [IQR: 4] in IBD and non-IBD groups, respectively ( Table 1) . All of the patients reported adherence to folic acid supplementation, and none reported use of tobacco, alcohol, or recreational drugs during pregnancy. Bowel preparation was used in 3/50 (6%) procedures. Sedation or anesthesia was used in 5/50 (10%) procedures. Of these, one procedure was performed under nurse-guided moderate sedation (meperidine and midazolam); three were performed under monitored anesthesia care with use of moderate sedation (midazolam, meperidine, fentanyl, or propofol); and one was performed under general anesthesia (propofol and intubation). Biopsies were performed in 86% of all cases. Median sigmoidoscopy scope insertion was 30 cm [IQR: 10]. A total of 8 endoscopies were performed in the first trimester, 26 in the second, and 16 in the third trimester. Of the seven patients without a prior diagnosis of IBD, the indication for performing lower endoscopy was to rule out new-onset IBD given symptoms of hematochezia.
There were no hospitalizations or pregnancy adverse events temporally associated with flexible sigmoidoscopy in either IBD or non-IBD patient groups. One intra-uterine fetal demise between 30 and 34 weeks gestational age (GA) (procedure at 10 weeks GA) and one elective termination in the second trimester (procedure at 13 weeks GA) occurred in the IBD group, but were not temporally or etiologically thought to be related to the sigmoidoscopy. Median GA at birth was 39 weeks in the IBD group [IQR 2] and 40.2 weeks in the non-IBD group [IQR 0.9, p = 0.03]. Rates of cesarean section delivery were 29.3% and 28.6% in IBD and non-IBD women, respectively ( Table 2 , p = 0.9). The rates of low birthweight (< 2700 gm) in infants born to IBD and non-IBD mothers were 11.8% and 0%, respectively ( Table 2 , p = 0.42).
In the IBD group, 88.4% of women had evidence of disease activity at the time of flexible sigmoidoscopy, with 62.7% of women showing evidence of moderate to severe disease. For the 20 women who were found to have severe disease, 11 women (55%) were initiated on biologic therapy, 1 woman (5%) underwent a switch in her biologic therapy, 6 women (30%) were started on systemic steroids, and 1 woman underwent a proctocolectomy during pregnancy. For the 7 women who were found to have moderate disease, 2 women (28.6%) were initiated on biologics, and 1 woman (14.3%) was started on systemic steroids. Only 3 of 11 women (27.3%) found to have mild disease were initiated on biologic therapy. Conversely, for the non-IBD pregnant patients who underwent a lower endoscopy, 5 patients (71.4%) were diagnosed with internal hemorrhoids, and the rest had normal endoscopic findings.
Noninvasive markers of inflammation were recorded and correlated with endoscopic findings. There was no correlation between values of white blood cell count (WBC) and endoscopic severity of inflammation. Hemoglobin trended toward a decline with increasing endoscopic severity and CRP, ESR, and fecal calprotectin rose with increasing endoscopic severity (Table 3 ).
Discussion
Consistent with prior studies, our work-the largest study to date of pregnant patients with known or suspected IBD undergoing flexible sigmoidoscopy-supports the safety of flexible sigmoidoscopy as a diagnostic procedure for patients with strong indications. An unsedated, unprepped flexible sigmoidoscopy without obstetric monitoring was found to be low risk and not associated with any maternal or fetal adverse events. These results reflect the combined experience of 11 different endoscopists and capture all 30 [10] 25 [5] trimesters of pregnancy. In total, approximately 78% of patients experienced a change in their therapy following the lower endoscopy. Women with IBD should have careful preconception counseling, optimization of medical therapy, and steroidfree clinical remission for at least 3 months prior to conception [3] . Despite best efforts, however, many women with IBD experience worsening of their disease activity during pregnancy. The current ASGE guidelines recommend deferring lower endoscopy to the second trimester or to the post-partum period; however, risks of IBD activity to the pregnancy call for timely endoscopic evaluation. This is why the American Gastroenterology Association Pregnancy Care Pathway recommends unsedated, unprepped flexible sigmoidoscopy as needed in any trimester in the appropriate patient with IBD [3] .
The safety of endoscopy was previously studied in a nationwide population-based cohort study by Ludvigsson et al. [15] . This studied 3052 pregnancies exposed to upper endoscopies, lower endoscopies, or endoscopic retrograde cholangiopancreatographies, and showed that exposure to any endoscopic procedure during pregnancy was associated with an increased risk of preterm birth and small for gestational age, independent of trimester. However, studies specifically studying the pregnant IBD patient population, which has increased rates of spontaneous abortions and pregnancy-related complications than their non-IBD counterparts, have been few and small in size. A matched IBD mothers 4/34 (11.8%) Non-IBD mothers 0/5 (0%, p = 0.42) Fetal demise Intra-uterine fetal demise between 30 and 34 weeks gestation (n = 1 IBD) Elective termination of pregnancy in 2nd trimester (n = 1 IBD) Rates of cesarean deliveries IBD 29.3% Non-IBD 28.6% (p = 0.9) case-control study of 42 IBD patients published by De Lima et al. [16] reported two spontaneous abortions that were thought to be temporally related to lower gastrointestinal endoscopy. However, the spontaneous abortion rate was higher in the control population of IBD patients not undergoing endoscopy, and overall there were no increased adverse outcomes for the mother or fetus in any trimester. In higher-risk groups such as pregnant patients presenting with red-flag symptoms, the decision to proceed with diagnostic lower endoscopy is frequently weighed against use of noninvasive alternatives such as fecal calprotectin. Although the fecal calprotectin is a commonly used biomarker for IBD, its sensitivity and specificity are insufficiently precise to be used as a primary diagnostic tool for IBD [7] [8] [9] [10] 17] , let alone to make major therapy changes in the gravid patient. Our study shows that while IBD patients with severe endoscopic inflammation tended to have higher levels of fecal calprotectin, this marker was not helpful in distinguishing between mild or moderate inflammation. We further note that 15% of the patients in this cohort had "negative" lower endoscopic findings. Changes in bowel habits and hemorrhoids are common in the pregnant patient, and these results highlight the importance of confirming the diagnosis prior to initiation or escalation of immunosuppression.
In line with previously published data, pregnant IBD women in this cohort had higher rates of Cesarean section delivery than their non-IBD counterparts. This finding is similar to the results of large population-based studies that showed that women with IBD have a 1.5 to 2-fold increase in the rate of Cesarean delivery [18] [19] [20] . Pregnant IBD women were also noted to have a slight reduction in median gestational age at birth by 1 week compared to their non-IBD counterparts. While this was a statistically significant difference, it is not a clinically significant one-both groups of women had a median gestational age of at least 39 weeks, a clinical timepoint after which adverse neonatal outcomes are seen to decrease [20] .
This study is limited by its sample size and retrospective nature. The absolute risk of adverse events following sigmoidoscopy in the general population is small, and as such our study is insufficiently powered to estimate these risks in this special population. We cannot exclude the possibility of confounding bias relevant to the decision of which patients should undergo lower endoscopy. Moreover, we note that this study was carried out at a 1532 [1559] Non-IBD (n = 0)
None measured tertiary care medical center with expertise in both IBD and obstetrics. In spite of these limitations, this study contributes significant additional case experience to the literature on this understudied and vulnerable population. Although pregnancy is a common phenomenon in the general population, interventional clinical studies in this group are rare precisely because of the risks-whether perceived or real. Although this attitude reflects an appropriate sensitivity toward this group, the gaps in knowledge and risk-averse climate in clinical practice can paradoxically lead to overly conservative guidance and lower-quality care. In the absence of controlled trials, we suggest that cohort studies such as this are essential to demystify the perceived risks of medically necessary procedures and increase awareness and engagement by both the clinical and research communities. We hope subsequent guidelines will reflect this approach.
Conclusion
In conclusion, this study adds to the growing body of data supporting the safety of lower endoscopy in pregnant patients presenting with signs and symptoms concerning for new-onset or worsening inflammatory bowel disease. Lower endoscopy in women with IBD during all trimesters of pregnancy is of low risk for mother and child. When indicated, this procedure should not be deferred as it directly impacts the medical decision making needed for optimal obstetric and gastrointestinal outcomes.
